glp 1 who should take GLP-1 nausea: How to handle GLP-1s' most common side effect Who is a good candidate

But its a long-term play: Payers must analyze and establish longer-term ROI Even if payers actively want to keep up with the wave of demand for GLP-1s to treat obesity, they ultimately must convince plan sponsors to buy in

That is a verifiability gap for the undisclosed partners, not confirmed wrongdoing, but it is a real limitation patients should be aware of before ordering

Non-Medicare plans may describe Ozempic as either a preferred brand (PB) or a non-preferred brand (NPB)

Abbreviations CVOTs: Cardiovascular outcome trials DPP-4 inhibitors: Dipeptidyl peptidase-4 inhibitors GLP-1RA: Glucagon-like peptide-1 receptor agonists SGLT-2 inhibitors: Sodium-glucose cotransporter 2 inhibitors MACE: Major cardiovascular events RR: Risk ratio HHF: Hospitalization for heart failure References IDF Diabetes Atlas 2021 10th edition